Back to top
more

Hims & Hers Health (HIMS)

(Real Time Quote from BATS)

$50.94 USD

50.94
33,976,191

-4.58 (-8.25%)

Updated Aug 6, 2025 02:30 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 246)

Industry: Medical Info Systems

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Zacks Equity Research

Hims & Hers Health, Inc. (HIMS) Rises Higher Than Market: Key Facts

by Zacks Equity Research

The latest trading day saw Hims & Hers Health, Inc. (HIMS) settling at $16.44, representing a +0.86% change from its previous close.

Zacks Equity Research

Hims & Hers Health, Inc. (HIMS) Stock Drops Despite Market Gains: Important Facts to Note

by Zacks Equity Research

Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $16.28, moving -1.75% from the previous trading session.

Zacks Equity Research

Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It

by Zacks Equity Research

Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Debanjana Dey headshot

Hims & Hers Stock Plunges 32.1% in Three Months: What's Next?

by Debanjana Dey

HIMS is enhancing its offerings and expanding the breadth of health and wellness products and services. However, macro challenges are likely to hurt its performance.

Zacks Equity Research

Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.

Zacks Equity Research

Here is What to Know Beyond Why Hims & Hers Health, Inc. (HIMS) is a Trending Stock

by Zacks Equity Research

Hims & Hers Health (HIMS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Zacks Equity Research

Is Trending Stock Hims & Hers Health, Inc. (HIMS) a Buy Now?

by Zacks Equity Research

Hims & Hers Health (HIMS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Zacks Equity Research

Twilio and Floor & Decor Holdings have been highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Twilio and Floor & Decor Holdings have been highlighted as Zacks Bull and Bear of the Day

Ethan Feller headshot

Eli Lilly: The Next $1 Trillion Market Cap Stock?

by Ethan Feller

Eli Lilly showcased the exceptional strength of its business during its quarterly earnings meeting on Thursday morning

Zacks Equity Research

Hims & Hers Health, Inc. (HIMS) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Hims & Hers Health (HIMS) delivered earnings and revenue surprises of 20% and 3.59%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Debanjana Dey headshot

Hims & Hers (HIMS) Gains 45.8% in Three Months: What's Next?

by Debanjana Dey

Hims & Hers (HIMS) is enhancing its offerings and expanding the breadth of health and wellness products and services. However, macro challenges are likely to hurt its performance.

Zacks Equity Research

Boston Scientific (BSX) Rides on Global Growth, Buyouts

by Zacks Equity Research

Boston Scientific's (BSX) Endoscopy business within MedSurg is gaining from strong worldwide demand for its broad range of GI and pulmonary treatment options.

Debanjana Dey headshot

Should You Buy Hims & Hers (HIMS) Stock Ahead of Q2 Earnings?

by Debanjana Dey

Continued solid uptake of Hims & Hers (HIMS) offerings and expanding subscriber base are likely to have driven its performance in the second quarter.

Zacks Equity Research

Hospital Business Recovery to Aid Haemonetics' (HAE) Q1 Earnings

by Zacks Equity Research

Haemonetics' (HAE) first-quarter fiscal 2025 results are likely to reflect the benefits of hemostasis management growth.

Zacks Equity Research

Hims & Hers Health, Inc. (HIMS) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Hims & Hers Health (HIMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Can RadNet's (RDNT) Service Fee Revenues Help Lift Q2 Earnings?

by Zacks Equity Research

RadNet's (RDNT) Imaging Center segment is likely to have gained from the increased reimbursement from commercial and capitated payors and strong procedure volumes in the second quarter of 2024.

Zacks Equity Research

Can Hims & Hers Health (HIMS) Run Higher on Rising Earnings Estimates?

by Zacks Equity Research

Hims & Hers Health (HIMS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Zacks Equity Research

Here's How Zimmer Biomet (ZBH) is Poised Ahead of Q2 Earnings

by Zacks Equity Research

Zimmer Biomet (ZBH) is expected to have witnessed procedure volume recovery banking on strategic product launches in the second quarter.

Zacks Equity Research

Hims & Hers Health, Inc. (HIMS) Stock Moves -1.14%: What You Should Know

by Zacks Equity Research

In the most recent trading session, Hims & Hers Health, Inc. (HIMS) closed at $22.51, indicating a -1.14% shift from the previous trading day.

Zacks Equity Research

Is Hims & Hers Health (HIMS) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Hims & Hers Health, Inc. (HIMS) and TransMedics (TMDX) have performed compared to their sector so far this year.

Zacks Equity Research

Here's How Charles River (CRL) is Placed Ahead of Q2 Earnings

by Zacks Equity Research

Growth across Microbial Solutions and Biologics Testing and CDMO businesses is likely to have contributed to Charles River's (CRL) Q2 revenues, offset by lower biopharmaceutical demand.

Zacks Equity Research

Quest Diagnostics' (DGX) Haystack Oncology Forges New MRD Deal

by Zacks Equity Research

Quest Diagnostics' (DGX) subsidiary, Haystack Oncology, partners on the use of its MRD technology.

Zacks Equity Research

How to Play Henry Schein (HSIC) Ahead of Q2 Earnings?

by Zacks Equity Research

Henry Schein (HSIC) is expected to deliver impressive sales in both its businesses in the second quarter of 2024, along with a steady pace of recovery from the cyber incident.

Zacks Equity Research

Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.